Treatment of stable chronic obstructive pulmonary disease

Protocol for a systematic review and evidence map

Claudia C. Dobler, Magdoleen H. Farah, Allison S. Morrow, Mouaz Alsawas, Raed Benkhadra, Bashar Hasan, Larry J. Prokop, Zhen Wang, Mohammad H Murad

Research output: Contribution to journalReview article

Abstract

Introduction Chronic obstructive pulmonary disease (COPD) is a progressive lung disease, usually caused by tobacco smoking, but other important risk factors include exposures to combustion products of biomass fuels and environmental pollution. The introduction of several new (combination) inhaler therapies, increasing uncertainty about the role of inhaled corticosteroids and a rapid proliferation of the literature on management of stable COPD in general, call for novel ways of evidence synthesis in this area. A systematic review and evidence map can provide the basis for shared decision-making tools and help to establish a future research agenda. Methods and analysis This systematic review will follow an umbrella systematic review design (also called overview of reviews). We plan to conduct a comprehensive literature search of Ovid MEDLINE (including epub ahead of print, in process and other non-indexed citations), Ovid Embase, Ovid Cochrane Database of Systematic Reviews and Scopus from database inception to the present. We will include systematic reviews that assessed the effectiveness of any pharmacological or non-pharmacological intervention on one or more patient-important outcomes and/or lung function in patients with stable COPD. For every intervention/outcome pair, one systematic review will be included. An a priori protocol will guide, which systematic reviews will be chosen, how their credibility will be evaluated, and how the quality of the body of evidence will be rated. Data will be synthesised into an evidence map that will present a matrix that depicts each available treatment for stable COPD with a quantitative estimate on symptoms/outcomes from the patient perspective, along with an indication of the size and certainty in the evidence. Ethics and dissemination Approval by a research ethics committee is not required since the review will only include published data. The systematic review will be published in a peer-reviewed journal.

Original languageEnglish (US)
Article numbere027935
JournalBMJ open
Volume9
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Chronic Obstructive Pulmonary Disease
Databases
Environmental Pollution
Nebulizers and Vaporizers
Research Ethics Committees
Therapeutics
Ethics
MEDLINE
Biomass
Lung Diseases
Uncertainty
Decision Making
Adrenal Cortex Hormones
Smoking
Pharmacology
Lung

Keywords

  • chronic obstructive pulmonary disease
  • evidence map
  • knowledge translation
  • non-pharmacological interventions
  • pharmacological interventions
  • umbrella review

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of stable chronic obstructive pulmonary disease : Protocol for a systematic review and evidence map. / Dobler, Claudia C.; Farah, Magdoleen H.; Morrow, Allison S.; Alsawas, Mouaz; Benkhadra, Raed; Hasan, Bashar; Prokop, Larry J.; Wang, Zhen; Murad, Mohammad H.

In: BMJ open, Vol. 9, No. 5, e027935, 01.05.2019.

Research output: Contribution to journalReview article

Dobler, Claudia C. ; Farah, Magdoleen H. ; Morrow, Allison S. ; Alsawas, Mouaz ; Benkhadra, Raed ; Hasan, Bashar ; Prokop, Larry J. ; Wang, Zhen ; Murad, Mohammad H. / Treatment of stable chronic obstructive pulmonary disease : Protocol for a systematic review and evidence map. In: BMJ open. 2019 ; Vol. 9, No. 5.
@article{2fe5224898fa493eabad6def3e08d4fd,
title = "Treatment of stable chronic obstructive pulmonary disease: Protocol for a systematic review and evidence map",
abstract = "Introduction Chronic obstructive pulmonary disease (COPD) is a progressive lung disease, usually caused by tobacco smoking, but other important risk factors include exposures to combustion products of biomass fuels and environmental pollution. The introduction of several new (combination) inhaler therapies, increasing uncertainty about the role of inhaled corticosteroids and a rapid proliferation of the literature on management of stable COPD in general, call for novel ways of evidence synthesis in this area. A systematic review and evidence map can provide the basis for shared decision-making tools and help to establish a future research agenda. Methods and analysis This systematic review will follow an umbrella systematic review design (also called overview of reviews). We plan to conduct a comprehensive literature search of Ovid MEDLINE (including epub ahead of print, in process and other non-indexed citations), Ovid Embase, Ovid Cochrane Database of Systematic Reviews and Scopus from database inception to the present. We will include systematic reviews that assessed the effectiveness of any pharmacological or non-pharmacological intervention on one or more patient-important outcomes and/or lung function in patients with stable COPD. For every intervention/outcome pair, one systematic review will be included. An a priori protocol will guide, which systematic reviews will be chosen, how their credibility will be evaluated, and how the quality of the body of evidence will be rated. Data will be synthesised into an evidence map that will present a matrix that depicts each available treatment for stable COPD with a quantitative estimate on symptoms/outcomes from the patient perspective, along with an indication of the size and certainty in the evidence. Ethics and dissemination Approval by a research ethics committee is not required since the review will only include published data. The systematic review will be published in a peer-reviewed journal.",
keywords = "chronic obstructive pulmonary disease, evidence map, knowledge translation, non-pharmacological interventions, pharmacological interventions, umbrella review",
author = "Dobler, {Claudia C.} and Farah, {Magdoleen H.} and Morrow, {Allison S.} and Mouaz Alsawas and Raed Benkhadra and Bashar Hasan and Prokop, {Larry J.} and Zhen Wang and Murad, {Mohammad H}",
year = "2019",
month = "5",
day = "1",
doi = "10.1136/bmjopen-2018-027935",
language = "English (US)",
volume = "9",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Treatment of stable chronic obstructive pulmonary disease

T2 - Protocol for a systematic review and evidence map

AU - Dobler, Claudia C.

AU - Farah, Magdoleen H.

AU - Morrow, Allison S.

AU - Alsawas, Mouaz

AU - Benkhadra, Raed

AU - Hasan, Bashar

AU - Prokop, Larry J.

AU - Wang, Zhen

AU - Murad, Mohammad H

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Introduction Chronic obstructive pulmonary disease (COPD) is a progressive lung disease, usually caused by tobacco smoking, but other important risk factors include exposures to combustion products of biomass fuels and environmental pollution. The introduction of several new (combination) inhaler therapies, increasing uncertainty about the role of inhaled corticosteroids and a rapid proliferation of the literature on management of stable COPD in general, call for novel ways of evidence synthesis in this area. A systematic review and evidence map can provide the basis for shared decision-making tools and help to establish a future research agenda. Methods and analysis This systematic review will follow an umbrella systematic review design (also called overview of reviews). We plan to conduct a comprehensive literature search of Ovid MEDLINE (including epub ahead of print, in process and other non-indexed citations), Ovid Embase, Ovid Cochrane Database of Systematic Reviews and Scopus from database inception to the present. We will include systematic reviews that assessed the effectiveness of any pharmacological or non-pharmacological intervention on one or more patient-important outcomes and/or lung function in patients with stable COPD. For every intervention/outcome pair, one systematic review will be included. An a priori protocol will guide, which systematic reviews will be chosen, how their credibility will be evaluated, and how the quality of the body of evidence will be rated. Data will be synthesised into an evidence map that will present a matrix that depicts each available treatment for stable COPD with a quantitative estimate on symptoms/outcomes from the patient perspective, along with an indication of the size and certainty in the evidence. Ethics and dissemination Approval by a research ethics committee is not required since the review will only include published data. The systematic review will be published in a peer-reviewed journal.

AB - Introduction Chronic obstructive pulmonary disease (COPD) is a progressive lung disease, usually caused by tobacco smoking, but other important risk factors include exposures to combustion products of biomass fuels and environmental pollution. The introduction of several new (combination) inhaler therapies, increasing uncertainty about the role of inhaled corticosteroids and a rapid proliferation of the literature on management of stable COPD in general, call for novel ways of evidence synthesis in this area. A systematic review and evidence map can provide the basis for shared decision-making tools and help to establish a future research agenda. Methods and analysis This systematic review will follow an umbrella systematic review design (also called overview of reviews). We plan to conduct a comprehensive literature search of Ovid MEDLINE (including epub ahead of print, in process and other non-indexed citations), Ovid Embase, Ovid Cochrane Database of Systematic Reviews and Scopus from database inception to the present. We will include systematic reviews that assessed the effectiveness of any pharmacological or non-pharmacological intervention on one or more patient-important outcomes and/or lung function in patients with stable COPD. For every intervention/outcome pair, one systematic review will be included. An a priori protocol will guide, which systematic reviews will be chosen, how their credibility will be evaluated, and how the quality of the body of evidence will be rated. Data will be synthesised into an evidence map that will present a matrix that depicts each available treatment for stable COPD with a quantitative estimate on symptoms/outcomes from the patient perspective, along with an indication of the size and certainty in the evidence. Ethics and dissemination Approval by a research ethics committee is not required since the review will only include published data. The systematic review will be published in a peer-reviewed journal.

KW - chronic obstructive pulmonary disease

KW - evidence map

KW - knowledge translation

KW - non-pharmacological interventions

KW - pharmacological interventions

KW - umbrella review

UR - http://www.scopus.com/inward/record.url?scp=85065392272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065392272&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2018-027935

DO - 10.1136/bmjopen-2018-027935

M3 - Review article

VL - 9

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 5

M1 - e027935

ER -